Wave Life Science have a disappointing update to share regarding our Huntington’s disease (HD) clinical candidates being studied in the PRECISION-HD1 (WVE-120101) and PRECISION-HD2 (WVE-120102) Phase 1b/2a clinical trials. After reviewing data from the PRECISION-HD2 trial, they have made the difficult decision to discontinue development of WVE-120102.